What is PT-141 (Bremelanotide)?

PT-141 is bremelanotide, a cyclic melanocortin receptor agonist and the active ingredient in the prescription product Vyleesi. [1][2][3]

The approved use is specific: acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is not a general libido enhancer for everyone. [1][2][3]

PT-141 is related to melanotan-style peptides through melanocortin biology, but its regulatory status and indication are different from unapproved tanning peptides. [1][2][3]

What PT-141 (Bremelanotide) is investigated for

PT-141 (Bremelanotide) evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Hypoactive sexual desire disorder

Injectable

82% Strong

HSDD has the highest-confidence PT-141/bremelanotide evidence and is distinct from broader sexual-function claims. [1][2][3][4]

Human evidence

Two randomized phase 3 trials and FDA labeling support bremelanotide for acquired, generalized HSDD in premenopausal women. [1][2][3][4]

Animal / mechanistic evidence

The clinical indication is supported by central melanocortin arousal biology, with the confidence driven by human trial and FDA evidence. [1][2][3][4]

Female sexual arousal and broader sexual dysfunction

Injectable

58% Emerging

Broader female sexual function is human-studied but less certain than the approved HSDD indication. [5][8][10]

Human evidence

Dose-ranging and arousal-disorder studies support broader female sexual-function discussion outside the final FDA-labeled HSDD population. [5][8][10]

Animal / mechanistic evidence

Central melanocortin arousal signaling provides the mechanism for broader sexual-function studies. [5][8][10]

Male erectile dysfunction

Injectable

50% Emerging

Male erectile-function support is narrower and lower confidence than HSDD. [14][2]

Human evidence

A randomized study evaluated bremelanotide in sildenafil nonresponders, but this is not the approved indication. [14][2]

Animal / mechanistic evidence

The rationale follows central melanocortin arousal pathways rather than peripheral vasodilator replacement. [14][2]

Evidence snapshot

Overall confidence

Strong

82%

Bremelanotide has strong support for its labeled HSDD population. That evidence does not establish broad libido, erectile-function, or performance use. [1][2][3][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

82%

Human evidence

Strong

FDA labeling and Phase 3 trials support acquired, generalized HSDD use in premenopausal women. [1][2][3][4]

34%

Animal / preclinical

Limited

Melanocortin receptor biology supports central desire-pathway effects. [1][2][3][4]

82%

Mechanism support

Strong

Bremelanotide activates melanocortin receptors in central pathways tied to sexual desire. The mechanism is brain desire signaling rather than local blood-flow mechanics alone. [1][2][3][4]

Forms & administration

PT-141 includes approved bremelanotide autoinjector labeling and separate compounded PT-141 discussions. Vyleesi label instructions are distinct from non-label protocol patterns. [3][15][1]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Vyleesi labeling uses 1.75 mg/0.3 mL subcutaneously per event. Common PT-141 discussions often list 1.75-2 mg in the same injectable event-based range. [3][15][1]

Frequency

Event-based use is the common cadence. Vyleesi labeling limits use to 1 dose per 24 hours and recommends no more than 8 doses per month. [3][15][1]

Timing Considerations

Event-based timing is the anchor: Vyleesi labeling uses at least 45 minutes before activity, while common PT-141 discussions often plan 4-6 hours ahead. [3][15][1]

Cycle Length

Single-dose effects are commonly logged over 6-72 hours. Vyleesi labeling calls for discontinuation after 8 weeks if symptoms do not improve. [3][15][1]

What to expect

Same day

Injectable PT-141 is event-timed, with the desired sexual-desire response occurring during the planned activity window when it responds. [1][2][3][4][15]

Weeks to months

Injectable event-based use may show clearer desire, distress, and relationship-context patterns across repeated eligible events. [1][2][3][4][15]

After stopping

Event-timed effects end with injectable PT-141 exposure, and baseline sexual-desire patterns may return. [1][2][3][4][15]

Safety profile

PT-141 has label-backed bremelanotide safety concerns plus separate compounded-product questions. Nausea, flushing, blood-pressure effects, pigmentation, pregnancy, and oral-medication interactions matter. [3][1]

Common side effects

Nausea [3][1]
Flushing [3][1]
Injection-site reactions [3][1]
Headache [3][1]
Vomiting [3][1]

Cautions

Hypertension / CVD [3][1]
Pregnancy [3][1]
Hyperpigmentation [3][1]
Oral medication absorption [3][1]

What we don't know

Compounded PT-141 products, non-label populations, and repeated use beyond label limits have a different safety profile from Vyleesi trials. [3][1]

Who PT-141 (Bremelanotide) is not for

Route-specific avoid and medical-review notes:

Uncontrolled hypertension
Uncontrolled hypertension warrants medical review or avoidance for PT-141 (Bremelanotide). [3][1][2]
Known cardiovascular disease per label use
Known cardiovascular disease per label use warrants medical review or avoidance for PT-141 (Bremelanotide). [3][1][2]
Pregnancy or breastfeeding without clinician oversight
Pregnancy or breastfeeding without clinician oversight warrants medical review or avoidance for PT-141 (Bremelanotide). [3][1][2]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Documented interactions

Oral medications
The Vyleesi label states bremelanotide may slow gastric emptying and affect absorption of oral medications. [3][1]
Oral naltrexone
The Vyleesi label says to avoid oral naltrexone-containing products for alcohol or opioid addiction because bremelanotide may reduce naltrexone exposure. [3][1]

Theoretical interactions

Blood-pressure / vasoactive drugs
Antihypertensives, stimulants, nitrates, or PDE5 inhibitors can make post-dose blood-pressure and heart-rate effects harder to manage; this is a route-specific cardiovascular caution. [3][1]
Nausea-active medications
Antiemetics, GLP-1 drugs, alcohol, or nausea-provoking supplements can change tolerability and attribution of nausea; this is a route-specific caution. [3][1]

Regulatory status

United States

In the U.S. as of 2026-06-21, Vyleesi bremelanotide injection is FDA-approved only for acquired, generalized HSDD in premenopausal women. Compounded PT-141, male use, and wellness protocols are outside that approved population. [3][15][16][19]

Route	FDA drug approval	503A compounding
Injectable	Approved Vyleesi bremelanotide injection is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women; compounded PT-141 and other populations are separate. [3][15][15]	Not Listed 503A compounding for PT-141 is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved. [3][15][15][16][19][20]

Injectable

FDA drug approval

Approved

Vyleesi bremelanotide injection is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women; compounded PT-141 and other populations are separate. [3][15][15]

503A compounding

Not Listed

503A compounding for PT-141 is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved. [3][15][15][16][19][20]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. A U.S. FDA approval does not automatically establish the same approved indication, route, or product status in those markets. [22][23][24][25]

Sports & competition

WADA does not list PT-141 here as S2 in the same way as GH or gonadotropins, but non-approved systemic, wellness, or compounded use can still require S0-style anti-doping review. [17][15][16][19][20]

How it works

PT-141, or bremelanotide, activates melanocortin receptors, especially central pathways tied to sexual desire. In practical terms, the approved subcutaneous mechanism is brain desire signaling rather than a local blood-flow mechanism alone. [1][2][3][4]

The same melanocortin pathway explains key safety and route caveats. Injectable exposure can produce nausea, flushing, transient blood-pressure effects, pigmentation-related biology, and patient-selection limits, so the mechanism should stay tied to labeled use and route-matched evidence. Administration timing, dose limits, and contraindications are part of how the pathway is used. [1][2][3][4]

Research gaps & open questions

What the current literature has not yet settled about PT-141 (Bremelanotide):

A key evidence gap is broader population evidence. [1][2][3][4]

A key evidence gap is long-term frequent off-label use safety. [1][2][3][4]

A key evidence gap is combination safety with PDE5 inhibitors or hormone therapy. [1][2][3][4]

Common questions

Is PT-141 FDA-approved?

Yes. Vyleesi bremelanotide is FDA-approved in the U.S. for acquired, generalized HSDD in premenopausal women. [15][16][3][1]

Is PT-141 approved for men?

No. PT-141 is not FDA-approved for men; the Vyleesi indication is limited to premenopausal women with acquired, generalized HSDD. [15][16][3][1]

Is PT-141 the same as Melanotan II?

No. They are related melanocortin peptides, but bremelanotide has its own drug label, route, indication, and safety limits. [15][16][3][1]

Myths & misconceptions

Myth

PT-141 is a universal libido booster.

Reality

The approved evidence is population- and indication-specific. [1][2][3][4]

Myth

It is only a sexual peptide, so cardiovascular status does not matter.

Reality

Blood-pressure and cardiovascular cautions are part of label interpretation. [1][2][3][4]

History & discovery

PT-141, developed as bremelanotide, came from melanocortin peptide work that separated sexual-desire signaling from tanning-focused melanocortin development. Its history is unusually clinical for a peptide-market term. [1][2][3][4]

Dose-finding and early human studies moved bremelanotide toward desire and distress endpoints in premenopausal women. That shaped the route, population, and endpoint choices for later trials. [1][2][3][4]

Two RECONNECT phase 3 trials and FDA labeling established Vyleesi for acquired, generalized HSDD in premenopausal women. The milestone narrowed approval to a specific use, route, and population. [1][2][3][4]

Published research 17 studies

[1]

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.

Obstet Gynecol, 2019 Nov. human clinical.

[2]

Bremelanotide: First Approval.

Drugs, 2019 Sep. review.

[3]

Vyleesi bremelanotide prescribing information

U.S. Food and Drug Administration. official guidance.

[4]

Bremelanotide (Vyleesi) for hypoactive sexual desire disorder.

Med Lett Drugs Ther, 2019 Jul 29. review.

[5]

Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.

Womens Health (Lond), 2016 Jun. human clinical.

[6]

The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.

J Womens Health (Larchmt), 2021 Apr. human clinical.

[7]

Safety Profile of Bremelanotide Across the Clinical Development Program.

J Womens Health (Larchmt), 2022 Feb. human clinical.

[8]

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

J Sex Med, 2006 Jul. human clinical.

[9]

Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.

J Womens Health (Larchmt), 2022 Mar. human clinical.

[10]

Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.

J Sex Med, 2019 Aug. human clinical.

[11]

Re: Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial.

J Urol, 2016 Nov. human clinical.

[12]

Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis.

Obstet Gynecol, 2018 Aug. review.

[13]

Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.

Front Med (Lausanne), 2026. review.

[14]

Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.

J Urol, 2008 Mar. human clinical.

[15]

Drugs@FDA/openFDA query for PT-141 (Bremelanotide)

U.S. Food and Drug Administration. database query.

[16]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[17]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.